肾癌生物和化学药物治疗的研究进展

被引：5

作者：

邝永龙

王德林

机构：

[1] 重庆医科大学附属第一医院泌尿外科

来源：

检验医学与临床 | 2009年 / 6卷 / 09期

关键词：

肾癌; 生物治疗; 肾癌化学药物;

D O I：

暂无

中图分类号：

R737.11 [肾、肾盂肿瘤];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：707 / 709

页数：3

共 9 条

[1]

Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma [J].

Jonasch, Eric ;

Stadler, Walter M. ;

Bukowski, Ronald M. ;

Hayes, Teresa G. ;

Varadhachary, Atul ;

Malik, Rajesh ;

Figlin, Robert A. ;

Srinivas, Sandy .

CANCER, 2008, 113 (01) :72-77

[2]

Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial [J].

Motzer, Robert J. ;

Escudier, Bernard ;

Oudard, Stephane ;

Hutson, Thomas E. ;

Porta, Camillo ;

Bracarda, Sergio ;

Gruenwald, Viktor ;

Thompson, John A. ;

Figlin, Robert A. ;

Hollaender, Norbert ;

Urbanowitz, Gladys ;

Berg, William J. ;

Kay, Andrea ;

Lebwohl, David ;

Ravaud, Alain .

LANCET, 2008, 372 (9637) :449-456

[3]

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre; open-label; randomised phase III trial.[J].Christopher Wood;Pramod Srivastava;Ronald Bukowski;Louis Lacombe;Andrei I Gorelov;Sergei Gorelov;Peter Mulders;Henryk Zielinski;Axel Hoos;Florentina Teofilovici;Leah Isakov;Robert Flanigan;Robert Figlin;Renu Gupta;Bernard Escudier.The Lancet.2008, 9633

[4]

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [J].

Escudier, Bernard ;

Pluzanska, Anna ;

Koralewski, Piotr ;

Ravaud, Alain ;

Bracarda, Sergio ;

Szczylik, Cezary ;

Chevreau, Christine ;

Filipek, Marek ;

Melichar, Bohuslav ;

Bajetta, Emilio ;

Gorbunova, Vera ;

Bay, Jacques-Olivier ;

Bodrogi, Istvan ;

Jagiello-Gruszfeld, Agnieszka ;

Moore, Nicola .

LANCET, 2007, 370 (9605) :2103-2111

[5]

A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma [J].

Bleumer, I ;

Oosterwijk, E ;

Oosterwijk-Wakka, JC ;

Völler, MCW ;

Melchior, S ;

Warnaar, SO ;

Mala, C ;

Beck, J ;

Mulders, PFA .

JOURNAL OF UROLOGY, 2006, 175 (01) :57-62

[6]

Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors.[J].Lee S. Rosen M.D.;David Gordon M.D.;N. Simon Tchekmedyian M.D.;Ronald Yanagihara M.D.;Vera Hirsh M.D.;Maciej Krzakowski M.D.;Marek Pawlicki M.D.;Paul de Souza M.D.;Ming Zheng Ph.D.;Gladys Urbanowitz M.B.A.;Dirk Reitsma M.D.;John Seaman Pharm.D..Cancer.2004, 12

[7]

AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma [J].